Connect
MJA
MJA

    Sentinel lymph node biopsy for melanoma: an important risk-stratification tool

    Samuel S Zagarella, Michael Sladden, Catalin Popescu and Michael Bigby
    Med J Aust 2015; 202 (2): 78. || doi: 10.5694/mja14.01569
    Published online: 2 February 2015

    To the Editor: The article by Gyorki and Henderson1 is misleading and inaccurate. The stated primary outcome of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1) was:

    • Samuel S Zagarella1
    • Michael Sladden2
    • Catalin Popescu3
    • Michael Bigby4

    • 1 Concord Hospital, Sydney, NSW.
    • 2 University of Tasmania, Launceston, TAS.
    • 3 Carol Davila University of Medicine and Pharmacy, Bucuresti, Romania.
    • 4 Beth Israel Deaconess Medical Center, Boston, Mass, USA.

    Competing interests:

    No relevant disclosures.

    Author
    remove_circle_outline Delete Author
    add_circle_outline Add Author
    Comment
    Do you have any competing interests to declare? *
    I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
    I/we agree to the Terms of use of the Medical Journal of Australia *
    Email me when people comment on this article
    Responses are now closed for this article.